Marc Brizuela

TL;DR: In vitro evidence is provided that suggests feasibility to repurpose the anticancer drug mitomycin C against MDR Gram-negative bacteria and that synergy was inherent to TOB-CIP and that neither tobramycin nor ciprofloxacin individually synergized with mitomyin C.

TL;DR: Results indicate that polybasic peptidomimetic-based adjuvants repurpose novobiocin and rifampicin as potent agents against priority MDR Gram-negative pathogens.

TL;DR: The modification of TOB-based hybrid adjuvants by replacing TOB domain by the pseudo-disaccharide nebramine (NEB) through selective cleavage of the α-d-glucopyranosyl linkage of ToB is reported.

TL;DR: The synthesis of polybasic peptide-levofloxacin conjugates based on antibiotic hybrids consisting of tobramycin appended to different fluoroquinolones that possess potential as stand-alone antimicrobials as well as adjuvants are reported.

TL;DR: It is revealed that dUSCLs can indirectly disrupt active efflux of chloramphenicol in P. aeruginosa and this along with their membrane-permeabilizing properties may explain the d USCLs synergistic combination with conventional antibiotics against Gram-negative bacteria.